her2 20 percent breast cancers test currently detect her2 levels subject recent patient heterogeneous tumor areas high low expression concern herceptin drug treat roughly 30 percent her2 overexpressing tumors effects avoided patients her2 abnormality think message complex process deal ability enrich patients likely respond far better not test nevins says biopsy collected diagnose cancer clinical studies including drug trials not collect samples initiating treatment nevins hopes change arguing point time stop process says not case collection biopsies enable development effective biomarkers absence tissue samples biomarker development impossible biomarker development studies enrich study population patients likely respond given drug increase likelihood